ES2611157T3 - Composiciones y métodos para la administración de oxígeno - Google Patents
Composiciones y métodos para la administración de oxígeno Download PDFInfo
- Publication number
- ES2611157T3 ES2611157T3 ES11189814.4T ES11189814T ES2611157T3 ES 2611157 T3 ES2611157 T3 ES 2611157T3 ES 11189814 T ES11189814 T ES 11189814T ES 2611157 T3 ES2611157 T3 ES 2611157T3
- Authority
- ES
- Spain
- Prior art keywords
- nox
- protein
- proteins
- nox protein
- rate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title description 3
- 229910052760 oxygen Inorganic materials 0.000 title description 3
- 239000001301 oxygen Substances 0.000 title description 3
- 239000000203 mixture Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 65
- 108090000623 proteins and genes Proteins 0.000 abstract description 65
- 230000035772 mutation Effects 0.000 abstract description 25
- 238000010494 dissociation reaction Methods 0.000 abstract description 23
- 230000005593 dissociations Effects 0.000 abstract description 23
- 102000001554 Hemoglobins Human genes 0.000 abstract description 10
- 108010054147 Hemoglobins Proteins 0.000 abstract description 10
- 230000009257 reactivity Effects 0.000 abstract description 10
- 241000282414 Homo sapiens Species 0.000 abstract description 4
- 241000282412 Homo Species 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 description 18
- 230000027455 binding Effects 0.000 description 17
- 150000003278 haem Chemical class 0.000 description 9
- 102220469353 Putative uncharacterized protein URB1-AS1_N74A_mutation Human genes 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 102220040905 rs150548839 Human genes 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 102000008015 Hemeproteins Human genes 0.000 description 2
- 108010089792 Hemeproteins Proteins 0.000 description 2
- 102000036675 Myoglobin Human genes 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000006701 autoxidation reaction Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101100121602 Caenorhabditis elegans gcy-35 gene Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 229910002547 FeII Inorganic materials 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 102220438223 c.233G>A Human genes 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
- C07K14/43545—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
- C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/102499—Blood gas standard or control
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Insects & Arthropods (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92150506P | 2006-05-22 | 2006-05-22 | |
| US921505P | 2006-05-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2611157T3 true ES2611157T3 (es) | 2017-05-05 |
Family
ID=38779160
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11189814.4T Active ES2611157T3 (es) | 2006-05-22 | 2007-05-21 | Composiciones y métodos para la administración de oxígeno |
| ES07795153.1T Active ES2525226T3 (es) | 2006-05-22 | 2007-05-21 | Composiciones y métodos para la administración de óxido nítrico |
| ES07795174T Active ES2399662T3 (es) | 2006-05-22 | 2007-05-21 | Composiciones y procedimientos para la administración de oxígeno |
| ES11189807.8T Active ES2610653T3 (es) | 2006-05-22 | 2007-05-21 | Composiciones y métodos para la administración de óxido nítrico |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07795153.1T Active ES2525226T3 (es) | 2006-05-22 | 2007-05-21 | Composiciones y métodos para la administración de óxido nítrico |
| ES07795174T Active ES2399662T3 (es) | 2006-05-22 | 2007-05-21 | Composiciones y procedimientos para la administración de oxígeno |
| ES11189807.8T Active ES2610653T3 (es) | 2006-05-22 | 2007-05-21 | Composiciones y métodos para la administración de óxido nítrico |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US8404632B2 (enExample) |
| EP (7) | EP2040740B1 (enExample) |
| JP (5) | JP5698905B2 (enExample) |
| CN (5) | CN101495134B (enExample) |
| AU (2) | AU2007268052B2 (enExample) |
| BR (2) | BRPI0711901A2 (enExample) |
| CA (2) | CA2653101C (enExample) |
| DK (4) | DK2463297T3 (enExample) |
| ES (4) | ES2611157T3 (enExample) |
| IN (2) | IN2013MN00600A (enExample) |
| NZ (4) | NZ594456A (enExample) |
| WO (2) | WO2007139791A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5698905B2 (ja) | 2006-05-22 | 2015-04-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 一酸化窒素の送達のための方法 |
| US20110243849A1 (en) * | 2010-04-02 | 2011-10-06 | Marletta Michael A | Heme-binding photoactive polypeptides and methods of use thereof |
| JP6322652B2 (ja) * | 2013-01-07 | 2018-05-09 | オムニオクス， インコーポレイテッド | Ｈ−ｎｏｘタンパク質の重合体形態 |
| SG10201908269SA (en) * | 2015-03-17 | 2019-10-30 | Omniox Inc | Modulation of tumor immunity by protein-mediated o2 delivery |
| DK3416673T3 (da) * | 2016-02-16 | 2023-01-23 | Omniox Inc | Modulation af hypoxi associeret med slagtilfælde |
| JP6467073B2 (ja) * | 2018-01-04 | 2019-02-06 | オムニオクス， インコーポレイテッド | Ｈ−ｎｏｘタンパク質の重合体形態 |
| WO2020037052A1 (en) | 2018-08-15 | 2020-02-20 | Omniox, Inc. | H-nox proteins for treating cardiovascular and pulmonary conditions |
| KR20210052389A (ko) | 2018-08-27 | 2021-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 다운스트림 정제에서의 라만 분광법의 사용 |
| UA129329C2 (uk) | 2019-06-25 | 2025-03-19 | Гіліад Сайєнсіз, Інк. | ЗЛИТІ БІЛКИ FLT3L-Fc |
| CN118178645A (zh) | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| CA3153636A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| AU2020412875A1 (en) | 2019-12-24 | 2022-06-23 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
| PH12022552122A1 (en) | 2020-02-14 | 2024-01-29 | Jounce Therapeutics Inc | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| AU2021264550A1 (en) | 2020-05-01 | 2022-11-17 | Gilead Sciences, Inc. | CD73 inhibiting 2,4-dioxopyrimidine compounds |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| KR20240023628A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| US11919869B2 (en) | 2021-10-29 | 2024-03-05 | Gilead Sciences, Inc. | CD73 compounds |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| ES2999273T3 (en) | 2022-03-17 | 2025-02-25 | Gilead Sciences Inc | Ikaros zinc finger family degraders and uses thereof |
| JP2025509662A (ja) | 2022-03-24 | 2025-04-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| KR20250004824A (ko) | 2022-04-21 | 2025-01-08 | 길리애드 사이언시즈, 인코포레이티드 | Kras g12d 조절 화합물 |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| AU2023409398A1 (en) | 2022-12-22 | 2025-06-05 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024663A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250100998A1 (en) | 2023-07-26 | 2025-03-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US6022849A (en) | 1987-05-16 | 2000-02-08 | Baxter Biotech Technology Saarl | Mutant recombinant hemoglobins containing heme pocket mutations |
| US5731454A (en) | 1990-02-12 | 1998-03-24 | Virginia Commonwealth University | Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood |
| WO1995027040A1 (en) | 1994-04-01 | 1995-10-12 | Unisyn Technologies, Inc. | Culture media additives for hollow fiber bioreactors |
| JP4583510B2 (ja) | 1997-02-28 | 2010-11-17 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 無細胞系による酸素輸送の最適化のための方法と組成物 |
| DE69839263T2 (de) | 1997-05-02 | 2009-04-30 | Baxter Biotech Technology S.A.R.L. | Hämoglobin-Mutanten mit verringertem Stickstoff(mon)oxid-Entfernungsvermögen |
| DE19837015C2 (de) * | 1998-08-14 | 2003-03-20 | Vasopharm Biotech Gmbh | Isolierte und gereinigte humane lösliche Guanylylcyclase alpha1/beta1 (hsGCalpha1/beta1) |
| US6773613B1 (en) | 1998-10-15 | 2004-08-10 | Sangart, Inc. | Method for production of stroma-free hemoglobin |
| DE60038631T2 (de) * | 1999-12-22 | 2009-06-10 | The Scripps Research Institute, La Jolla | Modulatoren und inhibitoren von angiogenese und vaskulärer durchlässigkeit |
| AU2001271536A1 (en) * | 2000-06-29 | 2002-01-14 | Incyte Genomics, Inc. | Adenylyl and guanylyl cyclases |
| US20030096240A1 (en) * | 2000-09-19 | 2003-05-22 | Ferid Murad | Genomic organization of mouse and human sGC |
| US6780849B2 (en) * | 2000-12-21 | 2004-08-24 | Scimed Life Systems, Inc. | Lipid-based nitric oxide donors |
| US20030153491A1 (en) | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| DE60333306D1 (de) * | 2002-08-30 | 2010-08-19 | Biorexis Pharmaceutical Corp | Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen |
| CN1660100A (zh) * | 2002-12-09 | 2005-08-31 | 上海倍艺医药科技有限公司 | 一种治疗糖尿病及其并发症的药物 |
| JP5698905B2 (ja) * | 2006-05-22 | 2015-04-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 一酸化窒素の送達のための方法 |
-
2007
- 2007-05-21 JP JP2009512098A patent/JP5698905B2/ja active Active
- 2007-05-21 EP EP07795153.1A patent/EP2040740B1/en active Active
- 2007-05-21 DK DK11189814.4T patent/DK2463297T3/en active
- 2007-05-21 AU AU2007268052A patent/AU2007268052B2/en active Active
- 2007-05-21 WO PCT/US2007/012184 patent/WO2007139791A2/en not_active Ceased
- 2007-05-21 ES ES11189814.4T patent/ES2611157T3/es active Active
- 2007-05-21 NZ NZ594456A patent/NZ594456A/xx unknown
- 2007-05-21 CA CA2653101A patent/CA2653101C/en active Active
- 2007-05-21 JP JP2009512107A patent/JP5698906B2/ja active Active
- 2007-05-21 DK DK07795153.1T patent/DK2040740T3/en active
- 2007-05-21 EP EP11189807.8A patent/EP2463294B1/en active Active
- 2007-05-21 ES ES07795153.1T patent/ES2525226T3/es active Active
- 2007-05-21 DK DK11189807.8T patent/DK2463294T3/en active
- 2007-05-21 NZ NZ573003A patent/NZ573003A/en unknown
- 2007-05-21 EP EP11189812A patent/EP2463296A1/en not_active Withdrawn
- 2007-05-21 DK DK07795174.7T patent/DK2032156T3/da active
- 2007-05-21 CN CN200780027797.2A patent/CN101495134B/zh active Active
- 2007-05-21 NZ NZ594457A patent/NZ594457A/xx unknown
- 2007-05-21 IN IN600MUN2013 patent/IN2013MN00600A/en unknown
- 2007-05-21 CN CN201610487363.1A patent/CN106075388B/zh active Active
- 2007-05-21 CN CN201410766335.4A patent/CN104689300B/zh active Active
- 2007-05-21 US US12/302,004 patent/US8404632B2/en active Active
- 2007-05-21 CA CA2653080A patent/CA2653080C/en active Active
- 2007-05-21 NZ NZ573004A patent/NZ573004A/en unknown
- 2007-05-21 CN CN200780027798.7A patent/CN101495506B/zh active Active
- 2007-05-21 EP EP11189808A patent/EP2463295A1/en not_active Withdrawn
- 2007-05-21 BR BRPI0711901-1A patent/BRPI0711901A2/pt not_active Application Discontinuation
- 2007-05-21 US US12/302,002 patent/US8404631B2/en active Active
- 2007-05-21 IN IN601MUN2013 patent/IN2013MN00601A/en unknown
- 2007-05-21 CN CN201810357346.5A patent/CN108273040A/zh active Pending
- 2007-05-21 EP EP11189818A patent/EP2474554A3/en not_active Withdrawn
- 2007-05-21 EP EP11189814.4A patent/EP2463297B1/en active Active
- 2007-05-21 EP EP07795174A patent/EP2032156B1/en active Active
- 2007-05-21 WO PCT/US2007/012133 patent/WO2007139767A2/en not_active Ceased
- 2007-05-21 BR BRPI0711767A patent/BRPI0711767B8/pt active IP Right Grant
- 2007-05-21 ES ES07795174T patent/ES2399662T3/es active Active
- 2007-05-21 AU AU2007268028A patent/AU2007268028B2/en active Active
- 2007-05-21 ES ES11189807.8T patent/ES2610653T3/es active Active
-
2013
- 2013-02-20 US US13/772,283 patent/US20130289252A1/en not_active Abandoned
- 2013-02-20 US US13/772,281 patent/US20130288970A1/en not_active Abandoned
-
2014
- 2014-09-04 JP JP2014180140A patent/JP6118772B2/ja active Active
- 2014-09-04 JP JP2014180132A patent/JP6118296B2/ja active Active
- 2014-09-17 US US14/489,395 patent/US9493526B2/en active Active
- 2014-09-18 US US14/490,597 patent/US9493527B2/en active Active
-
2016
- 2016-10-12 US US15/292,012 patent/US10202428B2/en active Active
-
2017
- 2017-03-27 JP JP2017061455A patent/JP6458070B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2611157T3 (es) | Composiciones y métodos para la administración de oxígeno | |
| JP5351889B2 (ja) | インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質 | |
| Perutz et al. | Stereochemistry of cooperative mechanisms in hemoglobin | |
| Yuan et al. | Lighting up carbon monoxide: fluorescent probes for monitoring CO in living cells. | |
| Magierowska et al. | Carbon monoxide (CO) released from tricarbonyldichlororuthenium (II) dimer (CORM-2) in gastroprotection against experimental ethanol-induced gastric damage | |
| KR101784030B1 (ko) | Tfpi 저해제 및 사용 방법 | |
| Stellwagen | Carboxymethylation of horse heart ferricytochrome c and cyanferricytochrome c | |
| JP2010513314A5 (enExample) | ||
| ATE152931T1 (de) | Zer-oxydenthaltende zusammensetzung, ihre herstellung und ihre verwendung | |
| WO2017027379A1 (en) | Method for diagnosisng cancer or cancer-associated thrombosis by measuring levels of h3cit in plasma | |
| ES2691086T3 (es) | Composiciones y métodos para el tratamiento de carboxihemoglobinemia | |
| WO2007117215A8 (en) | Binder for c-reactive protein | |
| Chaffotte et al. | The “pre-molten globule,” a new intermediate in protein folding | |
| Arias et al. | Minocycline and tigecycline form higher-order Ca2+ complexes of stronger affinity than tetracycline | |
| Winningham et al. | Evidence for intramolecular hydrogen bonding in. beta.-alanine derivatives of 2, 8-dimethylphenoxathiin 4, 6-dicarboxylic acid. Model studies for nucleation of parallel. beta.-sheets | |
| Krebs et al. | Conformational differences between the E1 and E2 states of the calcium adenosine triphosphatase of the erythrocyte plasma membrane as revealed by circular dichroism and fluorescence spectroscopy | |
| WO2023068193A1 (ja) | 解毒剤、解毒剤用キットおよび新規包接錯体 | |
| Matsui et al. | Discovery and structure-guided optimization of tert-butyl 6-(phenoxymethyl)-3-(trifluoromethyl) benzoates as liver X receptor agonists | |
| Zsila | Chaperone-like activity of the acute-phase component human serum α1-acid glycoprotein: inhibition of thermal-and chemical-induced aggregation of various proteins | |
| WO2001068069A3 (en) | Pharmaceutical composition comprising paracetamol | |
| Watanabe et al. | Unusual cyanide bindings to a heme-regulated phosphodiesterase from Escherichia coli: effect of Met95 mutations | |
| Sych et al. | Albumin-stabilized fluorescent silver nanodots | |
| CA2363958A1 (en) | Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction | |
| Akcan et al. | Engineering venom peptides to improve their stability and bioavailability | |
| Suntsova et al. | Structural features of proteins responsible for resistance of tryptophan residues to nitrosylation |